Cells Clause Samples

The "Cells" clause defines the specific units or compartments within a larger system, such as a warehouse, data center, or organizational structure, that are subject to the terms of the agreement. It typically outlines how these cells are identified, managed, or allocated, and may specify responsibilities or limitations related to each cell. By clearly delineating the scope and boundaries of each cell, this clause ensures clarity in operations and helps prevent disputes over usage, access, or responsibility.
POPULAR SAMPLE Copied 1 times
Cells. “Cells” means each of the five (5) designated cells described in the RAP within the 157 Acre Site, as delineated in Exhibit A.
View SourceView Similar (3)
Cells. In table 4 the relative fold expression changes with their ranges are presented for the genes studied. The expression of MRP1 was approximately 3 fold decreased upon 24 hr exposure of doxorubicin (mean fold change 0.32, range 0.18-0.57), see figure 1. No changes in expression were seen after 4 h of incubation. The expression of the other genes remained unchanged after treatment with doxorubicin both after 4 and 24 h of incubation. Although the range in fold change was relatively large, CPEC seemed to decrease the expression of MRP2 after a 24 h incubation period (mean 0.49, range 0.25-0.85), no changes were seen after 4 h of incubation. CPEC did not induce changes in expression of the other genes (4 and 24 h of incubation). Doxorubicin 24 hr Doxorubicin 4 hr CPEC 24 hr CPEC 4 hr MRP1 0.32 (0.18-0.57) 0.79 (0.31-1.45) 0.81 (0.39-1.30) 0.94 (0.34-2.30) MRP2 0.55 (0.23-1.09) 0.68 (0.28-1.12) 0.49 (0.24-0.85) 0.98 (0.46-2.34) Rac2 0.61 (0.23-1.14) 0.71 (0.19-1.77) 0.54 (0.21-1.16) 0.88 (0.27-2.93) P22phox 0.85 (0.28-1.27) 1.14 (0.45-2.37) 1.03 (0.53-1.80) 1.11 (0.56-2.5) Table 4 Relative fold changes in expression upon exposure to doxorubicin or CPEC normalized fold change (2-∆∆Ct) relative to untreated control (range)
View Source
Cells. During the Development Work, cells developed by Zarlink for the Circuits or proposed for use in the Circuits by Zarlink (collectively the “Cells”) will be made available upon request to Given. Given agrees to use the Cells only for the purpose of developing and simulating the system in which the Circuits will be used. Subject to Section 3.7, the Cells remain Zarlink’s property, and Given shall not use the Cells in other applications or disclose any information related to the Cells to a third party without prior written authorization by Zarlink.
View Source

Related to Cells

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Animals The Hirer shall ensure that no animals (including birds) except guide dogs are brought into the premises, other than for a special event agreed to by the Village Hall. No animals whatsoever are to enter the kitchen at any time.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • Probes Network hosts used to perform (DNS, EPP, etc.) tests (see below) that are located at various global locations.

  • Devices BNY Mellon will restrict the transfer of Customer Data from its network to mass storage devices. BNY Mellon will use a mobile device management system or equivalent tool when mobile computing is used to provide the services. Applications on such authenticated devices will be housed within an encrypted container and BNY Mellon will maintain the ability to remote wipe the contents of the container.